Ampersand-backed Nexelis to acquire AIT Bioscience.

Ampersand Capital Partners-backed Nexelis, a specialty provider offering high-quality preclinical and clinical immunology laboratory services, agreed to acquire AIT Bioscience, a provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields. Financial terms were not disclosed. "This is our fourth acquisition since 2018 and we are excited for AIT Bioscience to join the Nexelis growth story. AIT Bioscience has a scientifically strong team and operates within a geography that we see as an attractive location for future growth. AIT Bioscience's advanced testing capacity will help Nexelis further bolster its service offering in the bioanalytical segment and maintain competitive lead and turnaround times," Benoit Bouche, Nexelis President and Chief Executive Officer.